Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cyclacel Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CYCC
Nasdaq
2834
https://cyclacel.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
- Apr 1st, 2024 1:15 pm
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
- Mar 20th, 2024 2:05 pm
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 19th, 2024 8:05 pm
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
- Mar 13th, 2024 8:05 pm
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Mar 7th, 2024 2:15 pm
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
- Mar 6th, 2024 2:15 pm
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
- Feb 20th, 2024 2:15 pm
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
- Jan 30th, 2024 2:15 pm
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
- Jan 8th, 2024 2:15 pm
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
- Jan 2nd, 2024 2:15 pm
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
- Dec 22nd, 2023 2:15 pm
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
- Dec 18th, 2023 2:00 pm
Cyclacel Pharmaceuticals Announces Reverse Stock Split
- Dec 12th, 2023 9:05 pm
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
- Nov 30th, 2023 2:15 pm
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
- Nov 28th, 2023 10:15 pm
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript
- Nov 14th, 2023 3:46 pm
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
- Nov 13th, 2023 9:05 pm
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
- Nov 7th, 2023 2:15 pm
Q2 2023 Cyclacel Pharmaceuticals Inc Earnings Call
- Aug 10th, 2023 10:42 am
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
- Aug 9th, 2023 8:05 pm
Scroll